Wesbanco Bank Inc. Acquires New Shares in Exelixis, Inc. $EXEL

Wesbanco Bank Inc. bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 28,034 shares of the biotechnology company’s stock, valued at approximately $1,158,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Truist Financial Corp raised its stake in shares of Exelixis by 1.1% in the second quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock valued at $983,000 after acquiring an additional 250 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Exelixis by 0.3% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock worth $4,521,000 after purchasing an additional 274 shares during the last quarter. Richardson Financial Services Inc. lifted its stake in Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 292 shares during the last quarter. Evergreen Capital Management LLC grew its position in Exelixis by 6.4% during the 3rd quarter. Evergreen Capital Management LLC now owns 5,450 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 329 shares during the last quarter. Finally, Plato Investment Management Ltd raised its stake in Exelixis by 6.5% during the 2nd quarter. Plato Investment Management Ltd now owns 6,174 shares of the biotechnology company’s stock valued at $271,000 after acquiring an additional 377 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EXEL. TD Cowen reissued a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Citigroup lowered shares of Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. Leerink Partners upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective on the stock in a report on Tuesday, October 21st. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $45.00 target price on shares of Exelixis in a research report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Exelixis currently has a consensus rating of “Hold” and an average price target of $46.16.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 28,043 shares of Exelixis stock in a transaction on Friday, November 21st. The stock was sold at an average price of $42.58, for a total value of $1,194,070.94. Following the transaction, the executive vice president directly owned 374,029 shares in the company, valued at $15,926,154.82. The trade was a 6.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 72,230 shares of company stock worth $3,046,923. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Stock Down 2.2%

EXEL stock opened at $42.98 on Wednesday. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62. The stock has a market cap of $11.52 billion, a PE ratio of 18.14, a price-to-earnings-growth ratio of 0.74 and a beta of 0.42. The firm’s 50-day simple moving average is $43.69 and its 200 day simple moving average is $40.92.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The company had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. During the same period in the previous year, the firm earned $0.55 EPS. Exelixis’s revenue was up 5.6% on a year-over-year basis. Equities analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported Q4 EPS above consensus (reported $0.94 vs. estimates around $0.74–$0.77), reflecting margin improvement and stronger profitability year‑over‑year. Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Balance sheet & cash flow strength: operating cash generation and cash balances improved materially (cash and equivalents rose, strong operating cash flow), which supports reinvestment and pipeline funding. Exelixis (EXEL) Releases Q4 2025 Earnings
• Positive Sentiment: Analyst support: William Blair and other firms have reiterated bullish stances / buy ratings, citing solid execution and advancing pipeline that underpin 2026 earnings power. Analyst backing can buoy sentiment even after mixed results. Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
• Neutral Sentiment: Corporate update / outlook: Management presented a slide deck and described progress on the cabozantinib franchise and clinical milestones, positioning the company for growth in 2026 — an update investors will parse for timing of launches and label expansions. Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Positive media/valuation mentions: Exelixis surfaced in value/PEG screens and retail pieces highlighting it as a sub‑$50 healthcare pick, which may attract long‑only and retail interest. 4 Discounted PEG Value Stocks to Boost Your Portfolio’s Health
• Negative Sentiment: Revenue shortfall vs. some estimates: total Q4 revenue rose year‑over‑year but came in below certain consensus figures (~$598.7M reported vs. higher street estimates), which likely tempered upside from the EPS beat. Exelixis (EXEL) Releases Q4 2025 Earnings
• Negative Sentiment: Insider selling & mixed price targets: recent filings show several insider sales and a wide range of analyst targets (some low), which can create caution among investors despite overall bullish coverage. Exelixis (EXEL) Releases Q4 2025 Earnings
• Neutral Sentiment: Short‑interest data in the newsfeed appears garbled/insignificant; it is not a clear driver in this update. (No reliable days‑to‑cover signal provided.)

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.